Mauna Kea Technologies SA (0P5I.L)

0.3895 +0.0005 (+0.13%) As of 01:23PM BST. Market open.

Mauna Kea Technologies SA

9, rue d'Enghien
Paris 75010
France
33 1 48 24 03 45
https://www.maunakeatech.com

Sector(s): 
Industry: 
Full-time employees: 67

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Alexandre Loiseau Ph.D.	Co-Founder, CEO & Chairman	172.64k	N/A	N/A
Mr. Come de La Tour du Pin	Chief Financial Officer	N/A	N/A	N/A
Ms. Nathalie Lecoq	Chief Operating Officer	N/A	N/A	N/A
Mr. Frederic Banegas Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Mr. François Lacombe Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Daryl Donatelli	Vice President of Global Marketing & U.S. Sales	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Mauna Kea Technologies SA develops and markets medical devices in Europe and internationally. The company offers range of medical devices, which includes gastroenterology, pulmonology, urology, and drug development. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform which enables physicians to monitor progression of disease over time, assess point-in-time reactions, classify indeterminate areas, and guide surgical interventions. The company was incorporated in 2000 and is headquartered in Paris, France.

Corporate governance

Mauna Kea Technologies SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.